Monte Carlo design study of a moderated 252Cf source for in vivo neutron activation analysis of aluminium.
暂无分享,去创建一个
D. G. Lewis | S. Ryde | C. Evans | S. Natto
[1] M. Wilson,et al. Design of a californium-based epithermal neutron beam for neutron capture therapy. , 1993, Physics in medicine and biology.
[2] W. Morgan,et al. The development of a technique to measure bone aluminium content using neutron activation analysis. , 1993, Physiological measurement.
[3] S. Green,et al. A feasibility study of the in vivo measurement of aluminium in peripheral bone. , 1992, Physics in medicine and biology.
[4] J. Yanch,et al. Dosimetry of 252Cf sources for neutron radiotherapy with and without augmentation by boron neutron capture therapy. , 1992, Radiation research.
[5] H. Malluche,et al. Renal bone disease 1990: an unmet challenge for the nephrologist. , 1990, Kidney international.
[6] P. Altmann,et al. DISTURBANCE OF CEREBRAL FUNCTION BY ALUMINIUM IN HAEMODIALYSIS PATIENTS WITHOUT OVERT ALUMINIUM TOXICITY , 1989, The Lancet.
[7] K. Ellis,et al. In vivo monitoring of skeletal aluminum burden in patients with renal failure , 1988 .
[8] W. Morgan,et al. A clinical instrument for multi-element in vivo analysis by prompt, delayed and cyclic neutron activation using 252Cf. , 1987, Physics in medicine and biology.
[9] D. Chettle,et al. Techniques of in vivo neutron activation analysis , 1984, Physics in medicine and biology.
[10] J. O'hare,et al. Reversal of aluminum-induced hemodialysis anemia by a low-aluminum dialysate. , 1982, The New England journal of medicine.
[11] E. D. Williams,et al. Whole body aluminium in chronic renal failure and dialysis encephalopathy. , 1980, Clinical nephrology.
[12] P. S. Nagarajan,et al. Neutron dose distributions for californium-252 sources. , 1971, The International journal of applied radiation and isotopes.
[13] V. Krishaswamy. Calculation of the dose distribution about californium-252 needles in tissue. , 1971, Radiology.